2014
DOI: 10.1016/j.jns.2014.02.017
|View full text |Cite
|
Sign up to set email alerts
|

Management of relapsing–remitting multiple sclerosis in Latin America: Practical recommendations for treatment optimization

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
19
1
5

Year Published

2015
2015
2023
2023

Publication Types

Select...
9

Relationship

2
7

Authors

Journals

citations
Cited by 26 publications
(26 citation statements)
references
References 140 publications
1
19
1
5
Order By: Relevance
“…Multiple sclerosis (MS) is one of the most common, autoimmune, inflammatory, demyelinating diseases of the central nervous system in young adults, affecting approximately 2.3 million people worldwide [ 1 , 2 ]. Differences in the risk of MS and the disease course have been reported earlier in the Latin American population as compared to the well-studied Caucasian population [ 3 – 8 ]. For example, the Latin American MS population has higher age at disease onset and slower rate of progression of disability over time [ 4 ].…”
Section: Introductionmentioning
confidence: 97%
“…Multiple sclerosis (MS) is one of the most common, autoimmune, inflammatory, demyelinating diseases of the central nervous system in young adults, affecting approximately 2.3 million people worldwide [ 1 , 2 ]. Differences in the risk of MS and the disease course have been reported earlier in the Latin American population as compared to the well-studied Caucasian population [ 3 – 8 ]. For example, the Latin American MS population has higher age at disease onset and slower rate of progression of disability over time [ 4 ].…”
Section: Introductionmentioning
confidence: 97%
“…Se identificó al interferón beta-1A como el fármaco más recobrado dentro del grupo evaluado, dado que es un medicamento de primera línea sugerido por guías de práctica clínica latinoamericanas por reducir significativamente la mortalidad (7,14,18,19). Cabe aclarar que estas estimaciones de costos corresponden únicamente a los fármacos, y no incluyen otros costos directos de la enfermedad como rehabilitación, hospitalización por recaídas, gastos por parte del paciente y su familia, o costos indirectos como productividad perdida del paciente y su cuidador.…”
Section: Discussionunclassified
“…LA KOL report a fair amount of time during their patients' DMD initiation visit, which could be a good indicator of important therapy aspects being discussed with the patient and their families. KOL were adherent to LA guidelines about the scheduled frequency of patient's visits per year to the outpatient clinic [4]. On the other hand, most neurologists relied on self-report when evaluating adherence.…”
Section: Tablementioning
confidence: 99%